Alicia R Lopez Net Worth

The estimated Net Worth of Alicia R Lopez is at least $4.87 Миллион dollars as of 3 December 2010. Alicia Lopez owns over 96,656 units of Haemonetics stock worth over $1,522,682 and over the last 21 years Alicia sold HAE stock worth over $3,344,407.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Alicia Lopez HAE stock SEC Form 4 insiders trading

Alicia has made over 33 trades of the Haemonetics stock since 2003, according to the Form 4 filled with the SEC. Most recently Alicia exercised 96,656 units of HAE stock worth $3,874,939 on 3 December 2010.

The largest trade Alicia's ever made was exercising 96,656 units of Haemonetics stock on 3 December 2010 worth over $3,874,939. On average, Alicia trades about 5,391 units every 58 days since 2003. As of 3 December 2010 Alicia still owns at least 21,017 units of Haemonetics stock.

You can see the complete history of Alicia Lopez stock trades at the bottom of the page.

What's Alicia Lopez's mailing address?

Alicia's mailing address filed with the SEC is 400 WOOD ROAD, , BRAINTREE, MA, 02184.

Insiders trading at Haemonetics

Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy и Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.

What does Haemonetics do?

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right

Complete history of Alicia Lopez stock trades at Haemonetics

Haemonetics executives and stock owners

Haemonetics executives and other stock owners filed with the SEC include:

• Christopher Simon,
  President, Chief Executive Officer, Director
• William Burke,
  Chief Financial Officer, Executive Vice President
• Michelle Basil,
  Executive Vice President, General Counsel
• Josep Llorens,
  Senior Vice President - Global Manufacturing and Supply Chain
• Jacqueline Scanlan,
  Senior Vice President - Human Resources
• Richard Meelia,
  Independent Chairman of the Board
• Claire Pomeroy,
  Independent Director
• Charles Dockendorff,
  Independent Director
• Catherine Burzik,
  Independent Director
• Robert Abernathy,
  Independent Director
• Ellen Zane,
  Independent Director
• Mark Kroll,
  Independent Director
• Olga Guyette,
  Director – Investor Relations
• Michael Coyle,
  Independent Director
• Anila Lingamneni,
  Executive Vice President, Chief Technology Officer
• Dan Goldstein,
  VP, Corporate Controller
• Susan Bartlett Foote,
  Director
• Ronald G Gelbman,
  Director
• Neil 122 62 507 Ryding,
  EVP, Global Manufacturing
• David Fusco,
  EVP, Global Human Resources
• Brian R Burns,
  EVP, Global QA/RA
• Sandra Jesse,
  VP & CLO
• Ronald Merriman,
  Director
• Susan M Hanlon,
  V.P. Corporate Controller
• Kent J Davies,
  President, Global Markets
• Jonathan White,
  VP Research and Development
• Byron Selman,
  President, Global Markets
• Pedro P Granadillo,
  Director
• Said Bolorforosh,
  EVP, Chief Technology Officer
• William Granville,
  VP, Manufacturing
• Thomas Lawlor,
  President, Patient Division
• Brad Nutter,
  President & CEO
• Yutaka Sakurada,
  President, Japan & Asia
• Alicia R Lopez,
  Senior VP & General Counsel
• Lawrence C Best,
  Director
• Donna C E Williamson,
  Director
• Warren Jr Nighan,
  VP WW Q&ampR Affairs
• Ulrich Eckert,
  President, Europe & Latin Am
• Mikael Gordon,
  President, Haemonetics Europe
• Mark Beucler,
  
• Anthony Pare,
  
• Dave Helsel,
  VP, Global Manufacturing
• Harvey G Klein,
  Director
• Ryoji Sakai,
  President, Japan
• Ronald A Matricaria,
  Director
• Remi Corlin,
  President, Asia
• Mark A Popovsky,
  Vp, Corporate Medical Director
• Ronald J Ryan,
  Senior VP & CFO
• Stephen Swenson,
  VP & General Mgr, Global Plasm
• Peter M Allen,
  President, Donor Division
• Brian Concannon,
  President, Patient Division
• Kathleen Mc Daniel,
  EVP Global Human Resources
• James O'shaughnessy,
  
• Paul Black,
  Director
• Michael I Ruxin,
  VP Global Software Strategies
• Robert B Ebbeling,
  Senior VP, Manufacturing
• Joseph J Forish,
  VP, Human Resources
• Phillip John Brancazio,
  VP, Global Manufacturing
• Michael P Kelly,
  President, NA, Global Plasma
• William Roche Still,
  VP Strategic Mktg, & Bus. Dev.
• Benjamin L Holmes,
  Director
• Keiko Hattori,
  President, Haemonetics Japan
• Jan Conneely,
  VP & GM, Arryx, Inc.
• Christopher J Lindop,
  VP, Finance & CFO
• Laurie A. Miller,
  SVP, Human Resources
• Farris Maryanne Maunsell,
  VP, Chief Accounting Officer
• Lloyd Emerson Johnson,
  Director
• Stewart W Strong,
  President, Global Hospital
• James D Arecca,
  EVP, Chief Financial Officer
• Roy Galvin,
  President, Global Plasma & BC
• Diane M Bryant,
  Director